NCT05608876View on ClinicalTrials.gov

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Tigilanol Tiglate

Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.

Trial Locations (7)

2010

The Kinghorn Cancer Centre, Sydney

4102

Metro South Hospital and Health Service, via the Princess Alexandra Hospital, Brisbane

CF14 4XW

Cardiff and Vale University Health Board - University Hospital of Wales (UHW), Cardiff

SH1 4AB

East and North Hertfordshire NHS Trust (Incorporating Mount Vernon Cancer Centre) of Lister Hospital, Stevenage

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

Unknown

Guy's and St Thomas' NHS Foundation Trust, London

All Listed Sponsors
lead

QBiotics Group Limited

INDUSTRY